文献速递浆细胞疾病

骨髓NK细胞特征可预测接受达雷妥尤单抗为基础治疗的多发性骨髓瘤患者的MRD阴性

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.
PubMed 文献 · Blood · 2025-01-01

研究采用单细胞转录组学、流式细胞术和功能实验,分析多发性骨髓瘤患者诊断时及治疗期间骨髓NK细胞。诊断时CD16+细胞毒性NK细胞比例低与达雷妥尤单抗治疗后巩固治疗结束时的MRD阴性可能性降低相关,而在不含达雷妥尤单抗的对照组中NK细胞分布不能预测MRD阴性。

要点

  • 诊断时部分患者骨髓CD16+细胞毒性NK细胞比例降低,与达雷妥尤单抗存在时NK细胞脱颗粒和细胞因子产生减少相关。
  • 在CASSIOPEIA试验中,接受达雷妥尤单抗联合硼替佐米、沙利度胺、地塞米松及自体干细胞移植治疗的患者,诊断时CD16+骨髓NK细胞比例低与巩固治疗后MRD阴性可能性降低相关。
  • 对照臂(不含达雷妥尤单抗)中NK细胞分布不能预测MRD阴性。

核心结论

  • 骨髓NK细胞特征影响接受CD38靶向抗体免疫治疗的多发性骨髓瘤患者的治疗结局。

研究设计与样本

  • 研究采用单细胞转录组学、流式细胞术和功能实验,分析多发性骨髓瘤患者诊断时及治疗期间的骨髓NK细胞。
  • 研究纳入CASSIOPEIA试验中接受达雷妥尤单抗、硼替佐米、沙利度胺、地塞米松联合自体干细胞移植治疗的患者,并设置不含达雷妥尤单抗的对照臂。

主要发现

  • 诊断时部分患者CD16+细胞毒性NK细胞比例降低,与达雷妥尤单抗存在时NK细胞针对多发性骨髓瘤细胞的细胞因子产生和脱颗粒减少相关。
  • 诊断时CD16+骨髓NK细胞比例低与达雷妥尤单抗联合方案巩固治疗后MRD阴性可能性降低相关。
  • 对照臂中NK细胞分布不能预测MRD阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Natural killer (NK) cells are important effector cells in antibody-based immune therapies for multiple myeloma (MM) through antibody-dependent cellular cytotoxicity. Here, we used single-cell transcriptomics, flow cytometry, and functional assays to investigate the bone marrow NK-cell compartment of patients with MM at diagnosis and during treatment. We show reduced proportion of CD16+ cytotoxic NK cells in a subset of patients at diagnosis, which correlated with decreased cytokine production and NK-cell degranulation against MM cells in the presence of the anti-CD38 antibody daratumumab. In line with these findings, a low proportion of CD16+ bone marrow NK cells at diagnosis was associated with a reduced likelihood of achieving measurable (or minimal) residual disease (MRD) negativity after consolidation in patients treated with daratumumab, bortezomib, thalidomide, and dexamethasone in conjunction with autologous stem cell transplantation in the CASSIOPEIA trial. In contrast, NK-cell distribution did not predict MRD negativity in patients treated in the control arm without daratumumab. These findings highlight the impact of the bone marrow NK-cell compartment on therapeutic outcomes in patients with MM receiving immunotherapy with CD38-targeting antibodies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Korst CLBM, Tahri S, Duetz C, et al. The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy. Blood. 2025. PMID: 40019438. doi:10.1182/blood.2024026455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。